124 related articles for article (PubMed ID: 18297306)
1. Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model.
Lang SA; Brecht I; Moser C; Obed A; Batt D; Schlitt HJ; Geissler EK; Stoeltzing O
Langenbecks Arch Surg; 2008 May; 393(3):333-41. PubMed ID: 18297306
[TBL] [Abstract][Full Text] [Related]
2. Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes.
Lang SA; Schachtschneider P; Moser C; Mori A; Hackl C; Gaumann A; Batt D; Schlitt HJ; Geissler EK; Stoeltzing O
Mol Cancer Ther; 2008 Nov; 7(11):3509-18. PubMed ID: 19001434
[TBL] [Abstract][Full Text] [Related]
3. AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma.
Sathornsumetee S; Hjelmeland AB; Keir ST; McLendon RE; Batt D; Ramsey T; Yusuff N; Rasheed BK; Kieran MW; Laforme A; Bigner DD; Friedman HS; Rich JN
Cancer Res; 2006 Sep; 66(17):8722-30. PubMed ID: 16951188
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
5. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo.
Moser C; Lang SA; Mori A; Hellerbrand C; Schlitt HJ; Geissler EK; Fogler WE; Stoeltzing O
BMC Cancer; 2008 Jul; 8():206. PubMed ID: 18651980
[TBL] [Abstract][Full Text] [Related]
6. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell.
Huang M; Huang B; Li G; Zeng S
BMC Gastroenterol; 2018 Nov; 18(1):169. PubMed ID: 30400838
[TBL] [Abstract][Full Text] [Related]
7. [The inhibition effects of apatinib on cell proliferation, migration and apoptosis in esophageal carcinoma via Ras/Raf/MEK/ERK and JAK2/STAT3 pathways].
Feng Y; Zhou MY; Sun F; Kong Z; Wang J; Sun ZQ; Hu LJ; Wang JL; Hua Q; Yu JP
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):263-275. PubMed ID: 31014051
[No Abstract] [Full Text] [Related]
8. Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway.
Niu G; Sun L; Pei Y; Wang D
Anticancer Agents Med Chem; 2018; 18(4):583-590. PubMed ID: 29065844
[TBL] [Abstract][Full Text] [Related]
9. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth.
Lang SA; Moser C; Gaumann A; Klein D; Glockzin G; Popp FC; Dahlke MH; Piso P; Schlitt HJ; Geissler EK; Stoeltzing O
Clin Cancer Res; 2007 Nov; 13(21):6459-68. PubMed ID: 17975158
[TBL] [Abstract][Full Text] [Related]
10. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
Saidak Z; Giacobbi AS; Louandre C; Sauzay C; Mammeri Y; Galmiche A
Cancer Lett; 2017 Apr; 392():1-8. PubMed ID: 28161506
[TBL] [Abstract][Full Text] [Related]
11. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
Xiong YQ; Sun HC; Zhang W; Zhu XD; Zhuang PY; Zhang JB; Wang L; Wu WZ; Qin LX; Tang ZY
Clin Cancer Res; 2009 Aug; 15(15):4838-46. PubMed ID: 19638466
[TBL] [Abstract][Full Text] [Related]
12. Hsp90β promoted endothelial cell-dependent tumor angiogenesis in hepatocellular carcinoma.
Meng J; Liu Y; Han J; Tan Q; Chen S; Qiao K; Zhou H; Sun T; Yang C
Mol Cancer; 2017 Mar; 16(1):72. PubMed ID: 28359326
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
Lang SA; Klein D; Moser C; Gaumann A; Glockzin G; Dahlke MH; Dietmaier W; Bolder U; Schlitt HJ; Geissler EK; Stoeltzing O
Mol Cancer Ther; 2007 Mar; 6(3):1123-32. PubMed ID: 17363505
[TBL] [Abstract][Full Text] [Related]
14. miR-451 acts as a suppressor of angiogenesis in hepatocellular carcinoma by targeting the IL-6R-STAT3 pathway.
Liu X; Zhang A; Xiang J; Lv Y; Zhang X
Oncol Rep; 2016 Sep; 36(3):1385-92. PubMed ID: 27461244
[TBL] [Abstract][Full Text] [Related]
15. Rheum palmatum extract exerts anti-hepatocellular carcinoma effects by inhibiting signal transducer and activator of transcription 3 signaling.
Tan ZB; Fan HJ; Wu YT; Xie LP; Bi YM; Xu HL; Chen HM; Li J; Liu B; Zhou YC
J Ethnopharmacol; 2019 Mar; 232():62-72. PubMed ID: 30553869
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Thng CH; Chow P; Ong HS; Chung A; Soo KC
J Cell Mol Med; 2009 Aug; 13(8B):2673-2683. PubMed ID: 19220580
[TBL] [Abstract][Full Text] [Related]
17. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
Nam S; Kim H; Hong D; Park JB; Kim SJ
Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812
[TBL] [Abstract][Full Text] [Related]
18. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
19. Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice.
Lang SA; Moser C; Fichnter-Feigl S; Schachtschneider P; Hellerbrand C; Schmitz V; Schlitt HJ; Geissler EK; Stoeltzing O
Hepatology; 2009 Feb; 49(2):523-32. PubMed ID: 19085954
[TBL] [Abstract][Full Text] [Related]
20. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]